Literature DB >> 33119085

A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.

Alexander Pflug1, Marianne Schimpl1, J Willem M Nissink2, Ross C Overman3, Philip B Rawlins1, Caroline Truman4, Elizabeth Underwood3, Juli Warwicker3, Jon Winter-Holt2, William McCoull2.   

Abstract

The activation loop (A-loop) plays a key role in regulating the catalytic activity of protein kinases. Phosphorylation in this region enhances the phosphoryl transfer rate of the kinase domain and increases its affinity for ATP. Furthermore, the A-loop possesses autoinhibitory functions in some kinases, where it collapses onto the protein surface and blocks substrate binding when unphosphorylated. Due to its flexible nature, the A-loop is usually disordered and untraceable in kinase domain crystal structures. The resulting lack of structural information is regrettable as it impedes the design of drug A-loop contacts, which have proven favourable in multiple cases. Here, we characterize the binding with A-loop engagement between type 1.5 kinase inhibitor 'example 172' (EX172) and Mer tyrosine kinase (MerTK). With the help of crystal structures and binding kinetics, we portray how the recruitment of the A-loop elicits a two-step binding mechanism which results in a drug-target complex characterized by high affinity and long residence time. In addition, the type 1.5 compound possesses excellent kinome selectivity and a remarkable preference for the phosphorylated over the dephosphorylated form of MerTK. We discuss these unique characteristics in the context of known type 1 and type 2 inhibitors and highlight opportunities for future kinase inhibitor design.
© 2020 The Author(s).

Entities:  

Keywords:  MerTK; TAM; activation loop; activation segment

Mesh:

Substances:

Year:  2020        PMID: 33119085      PMCID: PMC7702301          DOI: 10.1042/BCJ20200735

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Rational protein crystallization by mutational surface engineering.

Authors:  Zygmunt S Derewenda
Journal:  Structure       Date:  2004-04       Impact factor: 5.006

2.  Exploiting structural information in patent specifications for key compound prediction.

Authors:  Christian Tyrchan; Jonas Boström; Fabrizio Giordanetto; Jon Winter; Sorel Muresan
Journal:  J Chem Inf Model       Date:  2012-06-11       Impact factor: 4.956

3.  XDS.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

Review 4.  Ten things you should know about protein kinases: IUPHAR Review 14.

Authors:  Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

5.  Structural basis of RIP1 inhibition by necrostatins.

Authors:  Tian Xie; Wei Peng; Yexing Liu; Chuangye Yan; Jenny Maki; Alexei Degterev; Junying Yuan; Yigong Shi
Journal:  Structure       Date:  2013-03-05       Impact factor: 5.006

6.  Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.

Authors:  Chalada Suebsuwong; Daniel M Pinkas; Soumya S Ray; Joshua C Bufton; Bing Dai; Alex N Bullock; Alexei Degterev; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2018-01-31       Impact factor: 2.823

Review 7.  Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.

Authors:  Kayla V Myers; Sarah R Amend; Kenneth J Pienta
Journal:  Mol Cancer       Date:  2019-05-14       Impact factor: 27.401

Review 8.  MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.

Authors:  Justus M Huelse; Diana M Fridlyand; Shelton Earp; Deborah DeRyckere; Douglas K Graham
Journal:  Pharmacol Ther       Date:  2020-05-14       Impact factor: 13.400

9.  Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

Authors:  Masamichi Mori; Naoki Kaneko; Yoko Ueno; Masaki Yamada; Ruriko Tanaka; Rika Saito; Itsuro Shimada; Kenichi Mori; Sadao Kuromitsu
Journal:  Invest New Drugs       Date:  2017-05-17       Impact factor: 3.850

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  2 in total

1.  Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors.

Authors:  Dominic J Lambo; Charlotta G Lebedenko; Paige A McCallum; Ipsita A Banerjee
Journal:  Mol Divers       Date:  2022-05-03       Impact factor: 2.943

2.  BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.

Authors:  Seung-Hyun Bae; Jung-Hoon Kim; Tae Hyun Park; Kyeong Lee; Byung Il Lee; Hyonchol Jang
Journal:  Exp Mol Med       Date:  2022-09-02       Impact factor: 12.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.